Why the study?
Endocrine dysfunction may contribute to the development, progression, and severity of NAFLD, warranting discussion of evidence across endocrine disorders and sex hormones.
This review highlights the significant role of endocrine dysfunction and sex hormones in the pathophysiology and progression of NAFLD.
NAFLD-endocrine associations may prompt comorbidity screening; leaves open causal direction and practice change pending prospective data.
Nonalcoholic fatty liver disease (NAFLD) has emerged as the most frequent chronic liver disease globally. NAFLD is strongly associated with metabolic syndrome and it has been recently suggested that to rename NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD). NAFLD has been studied in different endocrine axes and accumulating body of clinical and experimental studies have suggested that NAFLD is associated with polycystic ovarian syndrome (PCOS), hypopituitarism, growth hormone deficiency (GHD), hypogonadism and other endocrine disorders. In fact, endocrine dysfunction may be considered as the major contributor for the development, progression, and severity of NAFLD. In the present comprehensive review, we discussed the epidemiological and clinical evidence on the epidemiology, pathophysiology, and management of NAFLD in endocrine disorders, with an emphasis on the effects of sex-specific hormones/conditions as well as molecular basis of NAFLD development in these endocrine diseases.
No takes yet. Share an insight, caveat, or question.
Arefhosseini et al. (2022) studied this question.